
Rasem Mourad
Examiner (ID: 7274, Phone: (571)270-7770 , Office: P/2836 )
| Most Active Art Unit | 2836 |
| Art Unit(s) | 2836 |
| Total Applications | 617 |
| Issued Applications | 444 |
| Pending Applications | 46 |
| Abandoned Applications | 142 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 14896945
[patent_doc_number] => 20190292238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELL
[patent_app_type] => utility
[patent_app_number] => 16/256731
[patent_app_country] => US
[patent_app_date] => 2019-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 168164
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16256731
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/256731 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Jan 23, 2019 | Issued |
Array
(
[id] => 14583953
[patent_doc_number] => 20190219585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-18
[patent_title] => IMMUNOHISTOCHEMICAL PROXIMITY ASSAY FOR PD-1 POSITIVE CELLS AND PD-LIGAND POSITIVE CELLS IN TUMOR TISSUE
[patent_app_type] => utility
[patent_app_number] => 16/250721
[patent_app_country] => US
[patent_app_date] => 2019-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21349
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16250721
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/250721 | IMMUNOHISTOCHEMICAL PROXIMITY ASSAY FOR PD-1 POSITIVE CELLS AND PD-LIGAND POSITIVE CELLS IN TUMOR TISSUE | Jan 16, 2019 | Abandoned |
Array
(
[id] => 19263707
[patent_doc_number] => 20240207404
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => BISPECIFIC IN TANDEM RECEPTOR CAR AND METHOD FOR MODULATING THE TUMORAL MICROENVIRONMENT
[patent_app_type] => utility
[patent_app_number] => 17/420739
[patent_app_country] => US
[patent_app_date] => 2019-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9547
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420739
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/420739 | Bispecific in tandem receptor car and method for modulating the tumoral microenvironment | Jan 6, 2019 | Issued |
Array
(
[id] => 17859823
[patent_doc_number] => 11440969
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-13
[patent_title] => Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment
[patent_app_type] => utility
[patent_app_number] => 16/239663
[patent_app_country] => US
[patent_app_date] => 2019-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 27
[patent_no_of_words] => 61413
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 148
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239663
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/239663 | Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment | Jan 3, 2019 | Issued |
Array
(
[id] => 15666429
[patent_doc_number] => 10597432
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-24
[patent_title] => Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 16/237284
[patent_app_country] => US
[patent_app_date] => 2018-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 25
[patent_no_of_words] => 46004
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237284
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/237284 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | Dec 30, 2018 | Issued |
Array
(
[id] => 15163293
[patent_doc_number] => 10487126
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-11-26
[patent_title] => Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 16/237279
[patent_app_country] => US
[patent_app_date] => 2018-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 25
[patent_no_of_words] => 46032
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237279
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/237279 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | Dec 30, 2018 | Issued |
Array
(
[id] => 20622639
[patent_doc_number] => 12590137
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-31
[patent_title] => Meditope-enabled T cells
[patent_app_type] => utility
[patent_app_number] => 16/958614
[patent_app_country] => US
[patent_app_date] => 2018-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 50
[patent_figures_cnt] => 64
[patent_no_of_words] => 31536
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958614
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/958614 | Meditope-enabled T cells | Dec 30, 2018 | Issued |
Array
(
[id] => 14185285
[patent_doc_number] => 20190112347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-18
[patent_title] => Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 16/233284
[patent_app_country] => US
[patent_app_date] => 2018-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45939
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16233284
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/233284 | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | Dec 26, 2018 | Issued |
Array
(
[id] => 16375078
[patent_doc_number] => 20200323920
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-15
[patent_title] => IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19
[patent_app_type] => utility
[patent_app_number] => 16/956855
[patent_app_country] => US
[patent_app_date] => 2018-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21244
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956855
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/956855 | IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19 | Dec 18, 2018 | Abandoned |
Array
(
[id] => 14652713
[patent_doc_number] => 20190233485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-01
[patent_title] => T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/213368
[patent_app_country] => US
[patent_app_date] => 2018-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213368
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/213368 | T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF | Dec 6, 2018 | Abandoned |
Array
(
[id] => 14649461
[patent_doc_number] => 20190231859
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-01
[patent_title] => YEAST-MUC1 IMMUNOTHERAPEUTIC COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/211492
[patent_app_country] => US
[patent_app_date] => 2018-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35385
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16211492
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/211492 | Yeast-MUC1 immunotherapeutic compositions and uses thereof | Dec 5, 2018 | Issued |
Array
(
[id] => 14375237
[patent_doc_number] => 20190161531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-30
[patent_title] => Cell
[patent_app_type] => utility
[patent_app_number] => 16/211538
[patent_app_country] => US
[patent_app_date] => 2018-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14611
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16211538
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/211538 | Chimeric antigen receptor (CAR) comprising a CD19-binding domain | Dec 5, 2018 | Issued |
Array
(
[id] => 17241171
[patent_doc_number] => 20210360914
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => PRODUCTION OF CELL-BASED VACCINES
[patent_app_type] => utility
[patent_app_number] => 16/763878
[patent_app_country] => US
[patent_app_date] => 2018-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11852
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763878
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/763878 | PRODUCTION OF CELL-BASED VACCINES | Dec 2, 2018 | Abandoned |
Array
(
[id] => 17236680
[patent_doc_number] => 11180552
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-23
[patent_title] => CD47 antibodies and uses thereof for treating cancer
[patent_app_type] => utility
[patent_app_number] => 16/203809
[patent_app_country] => US
[patent_app_date] => 2018-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 56
[patent_figures_cnt] => 98
[patent_no_of_words] => 44858
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 167
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16203809
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/203809 | CD47 antibodies and uses thereof for treating cancer | Nov 28, 2018 | Issued |
Array
(
[id] => 14439721
[patent_doc_number] => 20190177733
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-13
[patent_title] => CANCER VACCINE FOR DOGS
[patent_app_type] => utility
[patent_app_number] => 16/197563
[patent_app_country] => US
[patent_app_date] => 2018-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10956
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16197563
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/197563 | CANCER VACCINE FOR DOGS | Nov 20, 2018 | Abandoned |
Array
(
[id] => 14043451
[patent_doc_number] => 20190077832
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-14
[patent_title] => NOVEL CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 16/196812
[patent_app_country] => US
[patent_app_date] => 2018-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16196812
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/196812 | Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers | Nov 19, 2018 | Issued |
Array
(
[id] => 17082079
[patent_doc_number] => 20210277085
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => TARGETED IMMUNOTOLERANCE
[patent_app_type] => utility
[patent_app_number] => 17/053979
[patent_app_country] => US
[patent_app_date] => 2018-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59025
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053979
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/053979 | TARGETED IMMUNOTOLERANCE | Nov 19, 2018 | Abandoned |
Array
(
[id] => 17020945
[patent_doc_number] => 20210244816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => CD47 BLOCKADE WITH RADIATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/759981
[patent_app_country] => US
[patent_app_date] => 2018-11-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8765
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759981
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/759981 | CD47 blockade with radiation therapy | Nov 4, 2018 | Issued |
Array
(
[id] => 14277305
[patent_doc_number] => 20190135937
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-09
[patent_title] => CD-38 Directed Chimeric Antigen Receptor Constructs
[patent_app_type] => utility
[patent_app_number] => 16/179850
[patent_app_country] => US
[patent_app_date] => 2018-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16179850
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/179850 | CD-38 directed chimeric antigen receptor constructs | Nov 1, 2018 | Issued |
Array
(
[id] => 17162987
[patent_doc_number] => 11149074
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-19
[patent_title] => Azide group-containing Fc protein
[patent_app_type] => utility
[patent_app_number] => 16/177839
[patent_app_country] => US
[patent_app_date] => 2018-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 19960
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16177839
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/177839 | Azide group-containing Fc protein | Oct 31, 2018 | Issued |